Including biomarkers for non-ADAMTS13 in routine clinical testing could benefit diagnosis and follow-up in patients with immune-mediated thrombotic thrombocytopenic purpura (TTP). Patients with immune ...
(MENAFN- ein presswire) the groundbreaking initiative, called fast4tma, will be launched for patients across the u.s. on june 24, 2023. groveport, ohio, united states, june 23, 2023/einpresswire / -- ...
A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing. X. Long Zheng, MD, PhD: How do you actually diagnose TTP [thrombotic thrombocytopenic purpura] ...
BEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced commercialization of the HemosIL AcuStar ADAMTS13 Activity Assay in the European Union and other ...
ADAMTS13 is a plasma metalloprotease that regulates the size of the von Willebrand factor (VWF) multimers. Genetic or acquired deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura (TTP) ...
A recombinant form of human ADAMTS13 approved for a different condition helped to save the life of a young mother with immune thrombotic thrombocytopenic purpura. A team led by investigators from ...
Inhibitory autoantibodies against ADAMTS13, a metalloproteinase enzyme that cleaves von Willebrand factor, are associated with the majority of nonfamilial cases of thrombotic thrombocytopenic purpura ...
The groundbreaking initiative, called FAST4TMA, will be launched for patients across the U.S. on June 24, 2023. Founded in 2014 as a grassroots effort, USTMA is on a mission to improve outcomes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback